Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin

Mette Høj Lauridsen; Trine Welløv Boesgaard; Oluf Pedersen; Torben Hansen; Birgitte Hertz

Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin

Translated title of the contribution: Diabetes in infants may be treated with sulfonylurea as a replacement for insulin

Mette Høj Lauridsen, Trine Welløv Boesgaard, Oluf Pedersen, Torben Hansen, Birgitte Hertz

Department of Biomedical Sciences

Abstract

A two-month-old Danish girl was admitted to the hospital in diabetic ketoacidosis and diagnosed with permanent neonatal diabetes mellitus (PNDM). She received continuous insulin treatment until she was genetically tested at the Steno Diabetes Centre. She carried a KCNJ11 Arg201His mutation, an activating mutation in the KCNJ11-gene which encodes the ATP-sensitive potassium subunit Kir6.2 in the beta cell which is responsible for insulin secretion. As recommended in the literature, she was successfully shifted from insulin therapy to sulfonylurea tablets at the age of three years and nine months. PNDM-patients should be screened for gene mutations regardless of current age.
Udgivelsesdato: 2009-Jun-1

Translated title of the contribution	Diabetes in infants may be treated with sulfonylurea as a replacement for insulin
Original language	Danish
Journal	Ugeskrift for læger
Volume	171
Issue number	23
Pages (from-to)	1923-4
Number of pages	1
ISSN	0041-5782
Publication status	Published - 2009

Cite this

@article{e52d087071fa11de8bc9000ea68e967b,

title = "Spaedb{\o}rnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin",

abstract = "A two-month-old Danish girl was admitted to the hospital in diabetic ketoacidosis and diagnosed with permanent neonatal diabetes mellitus (PNDM). She received continuous insulin treatment until she was genetically tested at the Steno Diabetes Centre. She carried a KCNJ11 Arg201His mutation, an activating mutation in the KCNJ11-gene which encodes the ATP-sensitive potassium subunit Kir6.2 in the beta cell which is responsible for insulin secretion. As recommended in the literature, she was successfully shifted from insulin therapy to sulfonylurea tablets at the age of three years and nine months. PNDM-patients should be screened for gene mutations regardless of current age. Udgivelsesdato: 2009-Jun-1",

author = "Lauridsen, {Mette H{\o}j} and Boesgaard, {Trine Well{\o}v} and Oluf Pedersen and Torben Hansen and Birgitte Hertz",

note = "Keywords: Child, Preschool; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Female; Glyburide; Humans; Hypoglycemic Agents; Infant; Insulin; Mutation; Potassium Channels, Inwardly Rectifying; Treatment Outcome",

year = "2009",

language = "Dansk",

volume = "171",

pages = "1923--4",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "23",

}

TY - JOUR

T1 - Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin

AU - Lauridsen, Mette Høj

AU - Boesgaard, Trine Welløv

AU - Pedersen, Oluf

AU - Hansen, Torben

AU - Hertz, Birgitte

N1 - Keywords: Child, Preschool; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Female; Glyburide; Humans; Hypoglycemic Agents; Infant; Insulin; Mutation; Potassium Channels, Inwardly Rectifying; Treatment Outcome

PY - 2009

Y1 - 2009

N2 - A two-month-old Danish girl was admitted to the hospital in diabetic ketoacidosis and diagnosed with permanent neonatal diabetes mellitus (PNDM). She received continuous insulin treatment until she was genetically tested at the Steno Diabetes Centre. She carried a KCNJ11 Arg201His mutation, an activating mutation in the KCNJ11-gene which encodes the ATP-sensitive potassium subunit Kir6.2 in the beta cell which is responsible for insulin secretion. As recommended in the literature, she was successfully shifted from insulin therapy to sulfonylurea tablets at the age of three years and nine months. PNDM-patients should be screened for gene mutations regardless of current age. Udgivelsesdato: 2009-Jun-1

AB - A two-month-old Danish girl was admitted to the hospital in diabetic ketoacidosis and diagnosed with permanent neonatal diabetes mellitus (PNDM). She received continuous insulin treatment until she was genetically tested at the Steno Diabetes Centre. She carried a KCNJ11 Arg201His mutation, an activating mutation in the KCNJ11-gene which encodes the ATP-sensitive potassium subunit Kir6.2 in the beta cell which is responsible for insulin secretion. As recommended in the literature, she was successfully shifted from insulin therapy to sulfonylurea tablets at the age of three years and nine months. PNDM-patients should be screened for gene mutations regardless of current age. Udgivelsesdato: 2009-Jun-1

M3 - Tidsskriftartikel

C2 - 19500515

SN - 0041-5782

VL - 171

SP - 1923

EP - 1924

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 23

ER -